Subscribe To
VRNA / Verona Pharma: Targeting The Large COPD Market
![Verona Pharma: Targeting The Large COPD Market](https://cdn.snapi.dev/images/v1/h/1/image-1390969440-2013320.jpg)
VRNA News
![Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/c/2/transcript15-2140527.jpg)
By Seeking Alpha
November 4, 2023
Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hah more_horizontal
![Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update](https://cdn.snapi.dev/images/v1/b/q/conf1-2110322.jpg)
By GlobeNewsWire
October 19, 2023
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-st more_horizontal
![Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround](https://cdn.snapi.dev/images/v1/h/n/default1-2089860.jpg)
By Zacks Investment Research
October 4, 2023
Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround
Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressur more_horizontal
![Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023 Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023](https://cdn.snapi.dev/images/v1/t/2/conf10-2086952.jpg)
By GlobeNewsWire
October 3, 2023
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, se more_horizontal
![Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023 Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023](https://cdn.snapi.dev/images/v1/p/o/conf4-2050581.jpg)
By GlobeNewsWire
September 6, 2023
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PD more_horizontal
![Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon](https://cdn.snapi.dev/images/v1/w/h/image-1409138328-2048616.jpg)
By Seeking Alpha
September 4, 2023
Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon
Verona Pharma has submitted a New Drug Application (NDA) for ensifentrine, a potential treatment for COPD, to the FDA. The FDA has a 60-day window to more_horizontal
![Verona Pharma: Financial Health And COPD Market Impact 2024 Verona Pharma: Financial Health And COPD Market Impact 2024](https://cdn.snapi.dev/images/v1/v/e/image-1435014860-2036787.jpg)
By Seeking Alpha
August 24, 2023
Verona Pharma: Financial Health And COPD Market Impact 2024
Verona Pharma is seeking FDA approval for its COPD treatment, ensifentrine, in 2024. The company has a strong financial position with substantial cash more_horizontal
![Verona Pharma: Targeting The Large COPD Market Verona Pharma: Targeting The Large COPD Market](https://cdn.snapi.dev/images/v1/h/1/image-1390969440-2013320.jpg)
By Seeking Alpha
August 8, 2023
Verona Pharma: Targeting The Large COPD Market
Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for i more_horizontal